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Abstract 
 
Background: Pneumonia is the leading cause of death in children worldwide and the most 
important pathogen causing the disease is the bacterium Streptococcus pneumoniae (the 
pneumococcus). This study aimed to determine the carriage rate and the resistance pattern of 
pneumococci in children with respiratory tract infection in the Moshi area in Tanzania, a 
region in which the pneumococcal vaccine was introduced in January 2013, and to relate the 
carriage rate to social factors and health status of the children.  
Methods: During October and November 2013, 187 randomly selected children under two 
years of age with symptoms of a respiratory tract infection (chills, cough, running nose, rapid 
or difficult breathing or sore throat) were included in the study. The children were recruited 
from three different health clinics in the Moshi area. A nasopharyngeal sample was taken 
from the children and a questionnaire was given to the parents. The samples were cultured at 
the clinical laboratory at Kilimanjaro Christian Medical Centre (KCMC) in Moshi, where 
isolates of pneumococci were identified and tested for antibiotic susceptibility. 
Results: The carriage rate of pneumococci in the nasopharynx among the children was 39%. 
One fourth of the pneumococcal isolates had reduced susceptibility against penicillin, while 
only 5.5% and 1.4% were non-susceptible against ceftriaxone and ampicillin, respectively.  
While almost all isolates were non-susceptible against co-trimoxazole (97%), the rate of 
pneumococci with reduced susceptibility against, erythromycin, tetracycline and clindamycin 
were 32%, 15% and 5.5%, respectively. No resistance was detected against quinolones. 
Carriage of pneumococci among the 187 children was not related to social factors (living 
conditions, parents’ level of education, breastfeeding etc.) or health status (antibiotic use, 
previous illness, vaccination status etc.). 
Discussion: The carriage rate is consistent with other studies in this area before the 
pneumococcal conjugate vaccination was initiated. The rather high rates of resistant bacteria, 
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as shown in this study, confirm that penicillin or co-trimoxazole should not be used as 
empirical treatment of pneumonia in this area, while amoxicillin could still be the first drug of 
choice.  
Conclusion: More restrictions on the antibiotic use are needed in the Moshi area and may 
lower the resistant rates.  
 
Background 
 
Children mortality rate is still high in many parts of the world and the leading cause of death 
is pneumonia (1). Every year there are about 120 million episodes of pneumonia in children 
under five years of age and children under two are especially vulnerable. Pneumonia causes 
about 1. 3 million deaths in children under five years of age, the majority occur in developing 
countries. The pneumonia incidence is greatly associated with poverty and 43% of the deaths 
from pneumonia occur in the Sub-Saharan Africa (2).  
 
Three important risk factors for developing pneumonia in children are: Under nutrition, 
suboptimal breastfeeding and zinc deficiency (3). These risk factors are shared with other 
childhood diseases such as diarrhea (3). Patients with immunodeficiencies including HIV is 
another vulnerable group for developing pneumonia (4). The HIV positive children are 
especially susceptible to bacterial pneumonia and infections with antibiotic resistant bacteria 
are also more common (2). Other risk factors for developing pneumonia include low-birth 
weight, cooking food on solid fuel, crowding, low maternal education, limited access to care 
and passive care-seeking behavior (3). 
 
A study from north-eastern Tanzania in 2012 identified factors that are associated with a more 
severe form of pneumonia. These factors included young age, malnutrition, low parental 
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education and low socioeconomic status (5).  Other important host-factors that strongly predict 
child survival in general are; living in rural areas, poor quality of water and bad sanitation (6, 
7). 
 
The most common bacteria that cause pneumonia is Streptococcus pneumoniae (the 
pneumococcus) (8), but other bacteria such as Haemophilus influenzae and viruses such as 
Influenza viruses and respiratory syncytial viruses (RSV)  may also cause the disease (3). The 
pneumococcus is also the leading cause of meningitis and sepsis in children and accounts for 
about 11% of all childhood deaths worldwide. The highest rate of pneumococcal mortality is 
in Africa (8). Worldwide, S. pneumoniae is estimated to account for about 18% of the severe 
cases and 33% of the deaths from pneumonia each year (2).  
 
An infection with S. pneumoniae cannot occur without the preceding colonization of the 
nasopharyngeal mucosa (9, 10). The colonization is a dynamic process when it comes to 
duration of carrying different strains (4). However, carriage in itself is not a risk factor for 
disease, especially not in children (9). Humans are the natural host for the pneumococci (11). 
Together with other bacteria such as Moraxella cattarrhalis and Haemophilus influenzae, S. 
pneumoniae constitutes the commensal flora of the nasopharynx in children. Nasopharyngeal 
carriage also enables horizontal spread between people in the society (4). The children are 
often asymptomatic carriers and therefore constitute the reservoir for these bacteria in the 
population. The bacteria are spread mainly in the child population (12), and the colonization 
rate varies greatly between different populations (9). The carriage rate of the pneumococcus 
increases during the first years of life, reaching a peak in children aged 2-3 years, after which 
it declines in older children (10). 
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Infection with S. pneumoniae is a complex process involving bacterial virulence, viral 
interplay and host-specific factors (9). The bacteria spread through aerosol droplets and close 
contact. From time to time the bacteria succeed in escaping the immune system, are aspirated 
and cause pneumonia (4). Pneumonia often starts with a viral infection in the upper 
respiratory tract, which usually gives symptoms of a common cold, such as cough and 
running nose. The infection then proceeds downward to the lungs enabling a secondary 
bacterial infection, pneumonia, which can be much more severe and even lethal (1). 
 
Predictors of carriage are crowding, family size, number of siblings, income, smoking and 
previous antibiotic use (4). Recent antibiotic may lead to higher rates of carriage and 
especially carriage of antibiotic resistant strains (4), although other studies show lower rates 
of colonization following antibiotic treatment (13-15). The carriage rate is also higher in HIV 
positive children (13). The carriage proportion also increases during a viral respiratory tract 
infection, and symptoms like cough and coryza are positively associated with carriage (4, 13). 
The carriage rate also varies with season and is highest during the cold season, which could be 
a confounder for crowding, since people tend to stay inside more during the cold (16). In low-
income countries both the carriage of the bacteria and its disease manifestations are more 
common than in high-income countries (9).  
 
Early diagnosis and antibiotic treatment can prevent many deaths from pneumonia (17), 
however, in many countries, treatment of pneumococcal infections has become more 
challenging due to high rates of S. pneumoniae resistant to penicillin (7). Resistance is driven 
by the global spanding misuse of antibiotics which in many low-income countries is apparent 
by the wide-spread over the counter selling of antimicrobials. The resistance was earlier 
contained in microorganisms found in hospitals (nosocomial infections) but is now prevalent 
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in the community and even carried among healthy individuals. The resistance seems to be 
higher in urban settings rather than rural (18). The first line treatment of pneumonia has 
earlier been either penicillin or co-trimoxazole (trimethoprim-sulphamethoxazole). These 
antibiotics were both cheap and had few side-effects (7), but now since the rate of 
pneumococci with reduced susceptibility against penicillin and co-trimoxazole is high in 
many low-income countries the first line drug is instead amoxicillin (ampicillin) (2). The 
increasing problem with antibiotic resistance is especially challenging for low-income 
countries that may not afford the more expensive second-line drugs (18). In a study from Dar 
es Salaam in 2012 more than two thirds of the pneumococci isolates from healthy children 
were non-susceptible to penicillin. High resistance rates to several other antibiotics were also 
shown, especially co-trimoxazole (83%). The multi-drug resistance was 17% among the 
isolates, defined as resistance to three or more antibiotics (11).  
 
Infection as well as carriage of the pneumococcus can be prevented through vaccination (9). 
Many countries now use the pneumococcal conjugate vaccine in their general child 
vaccination programmes (19), which has decreased the incidence of invasive pneumococcal 
disease (13). Not only the vaccinated individual but also other persons in the vaccinated 
community are protected, through so called herd immunity (4, 12). There are 94 different 
serotypes based on differences in the pneumococcal capsule (9, 20). The 13-valent vaccine 
covers 13 of these serotypes, namely: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F 
(12). The vaccine is designed to cover the serotypes most often isolated from invasive disease 
(9) and also the serotypes that most frequently carry antibiotic resistance (21).  In general; the 
serotypes that are carried asymptomatically are carried for a longer time than the serotypes 
that more frequently cause disease (9).  The serotype distribution differs geographically which 
makes it very important with local studies. In Dar es Salaam the most prevalent serotypes 
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found in the nasopharynx of children are 19F, 6B and 9V. Globally, these serotypes are the 
most common ones to colonize children (11).  
 
In countries using the pneumococcal conjugate vaccine, the pneumococcal serotypes present 
in the vaccines have decreased among the disease isolates (22),  but at the same time the 
prevalence of non-vaccine serotypes have increased (13). Immunization also protects the 
community from pneumococcal resistance by decreasing the circulation of resistant strains, 
but also through a decreased over-all use of antibiotics (21). Many low-income countries are 
about to include the pneumococcal conjugate vaccine in the vaccination programme of the 
children (23). Tanzania introduced the pneumococcal conjugate vaccine, PCV 13 in January 
2013. The outcome is at present uncertain since the vaccine is designed for high-income 
countries that may have another distribution of serotypes (7, 23). Further studies on serotype 
distribution on both carried and invasive strains in low-income countries are therefore 
necessary (4). Several pathogens that cause pneumonia are vaccine-preventable, including; H. 
influenzae type B, influenza virus and measles. Out of these, S. pneumoniae is the most 
important pathogen (2). Since preventable, it is a reasonable approach if trying to accomplish 
the Millennium Development Goal 4, which strives at reducing the under five mortality by 
two thirds before 2015 (3, 8). 
 
In a study from Kenya in 2012 the carriage prevalence rate was 66%. Among the serotypes 
found, only 59% were serotypes covered by the Pneumococcal Conjugate Vaccine, PCV 13. 
This raises the question of whether vaccine-introduction is a benefit or not. The outcome 
depends on the circulation of non-vaccine serotypes and their ability to colonize the 
nasopharynx and from there cause invasive disease (13). 
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Most studies conducted in developing countries earlier are hospital-based, which creates an 
unrepresentative study population (2). It is easy to both over- and underestimate the true 
incidence of childhood pneumonia. Studies on pneumonia risk factors in low- and middle 
Income Countries are scarce and the risk factors are often not independent which will lead to 
an over-estimation of each risk factor. On the other hand is it easy to under-estimate the 
disease burden caused by S. pneumoniae due to limited access to the pathogen, difficulties in 
transporting the specimen and culturing limitations (8). There are great difficulties in 
determining the etiological agents from the infection site (9). The lung, the site of infection, is 
a closed organ only in contact with the surroundings through the naso- and oropharynx. 
Sampling from the sputum or the nasopharynx is a possibility, but the result is complicated 
since the pathogens causing pneumonia are also common in the nasopharynx of children, 
causing no symptoms at all (3). However, pneumococcal disease is often preceded by carriage 
of a homologous strain (10), and the asymptomatic colonization with pneumococci gives an 
idea of the invasive strains circulating in the community and the rate of antibiotic resistance 
(11). Techniques like PCR may be a help to detect pneumococci in respiratory samples, but is 
also problematic since you tend to find many different pathogens, which leads to difficulties 
in establishing the causative agent. The availability to PCR methods is also highly restricted 
in low-income countries. 
 
Many studies look before and after immunization with the Pneumococcal Conjugate Vaccine 
to determine how big the disease burden for each etiological agent is. These trials are not 
without problems, since the introduction of a new vaccine often comes with big resources, 
which of course contribute to an improved health in general (3). About 12 % of the 
pneumonia cases become severe cases. This is a 25 % reduction from 2000 till 2010, a trend 
seen in many Low-and middle-income countries (3). This is supported by the fact that 
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exposure to the most important risk factors also decreased during that period of time. This is 
probably due to the improved overall quality of life in many of these countries. However, the 
proportion of severe cases increased which could mean that the most vulnerable in the society 
remains in poverty and more effort needs to be directed towards that group (3). Combating 
pneumonia includes reducing the risk factors, immunization and case management. Since it is 
more common in children younger than two, interventions should be focused on improving 
vaccination-programs, breastfeeding and childhood nutrition (2). 
 
Tanzania 
 
The Democratic Republic of Tanzania, situated in eastern Sub-Saharan Africa has a 
population of 43 million people. Tanzania has had a fast population growth, due to a high 
fertility rate and a declining mortality rate. Almost half of the population is under 15 years of 
age and only 4% are over 65 years. The mean number of births per woman is 5.4 children and 
the birth rate is highest in rural areas, among the lowest wealth quintile and among the women 
with the lowest education. The life-expectancy at birth is only 51 years (17). Despite an 
economical growth the past years, Tanzania remains a poor country with more than 75% 
living in rural households. Tanzania also remains highly aid-dependant and developmental 
funding constitutes 14% of the country’s total GDP (24). 
In 2010 the under-5 mortality rate was 81 per 1000 live births which is a big progress towards 
reaching the forth Millennium Development Goal of reducing the under five mortality rate by 
two thirds before 2015. In Tanzania the most common cause of death in children is malaria, 
followed by pneumonia (25). There are big differences within the country, with the lowest 
figures in the northern zone with an under five mortality rate of 58 per 1000 live births (17).  
The current general child vaccination programme includes vaccinations against diphtheria, 
pertussis, tetanus, polio and measles. BCG against tuberculosis is also given at birth. Since 
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2009 vaccination against H. influenzae type B and Hepatitis B are included in the general 
child vaccination programme. The latest addition is the Pneumococcal Conjugate Vaccine 
PCV13 which was introduced in January this year. Currently, the first dose is given when the 
child is six weeks old, the second at ten weeks and the third and final dose is given when the 
child is 14 weeks old. In the Kilimanjaro region 94% of the children aged 1-2 years have got 
all the basic vaccinations based on either the child’s health cards or the mothers’ verbal report 
(17). The country is divided into 21 regions and 113 districts. The health care is divided into 
dispensaries and health centres at the lowest level, followed by district hospitals, regional 
hospitals and finally at the highest levels the national referral hospitals. The health care often 
lacks medical equipments and drugs as well as health care staff. Half of the health care 
spending comes from out of pocket payment and this is a heavy burden for people, especially 
on the poorest (26). As stated earlier the incidence of pneumonia and its disease 
manifestations vary greatly between regions and is highest in Africa and South-east Asia.15 
countries account for almost two thirds of the total incidence as well as mortality in 
pneumonia and Tanzania is one of those countries (2).  
 
Knowing of the local resistance rates and serotype distribution is crucial when determining 
empirical treatment and designing vaccines, especially in low-income countries where studies 
are scarce but the disease burden is heaviest. The increasing antibiotic resistance must be 
frequently monitored and local studies looking at the resistance rates are needed (27). This 
study is highly topical since Tanzania has recently introduced the pneumococcal conjugate 
vaccine, PCV 13 in their general child vaccination programme and the outcome is at present 
uncertain. Few studies have been conducted in the Moshi area before, and they have all shown 
high resistance rates to several antibiotics which is a big threat against successfully treating 
the children of this region. 
12 
 
Aim 
 
• To investigate the colonization rate and antibiotic susceptibility of S. pneumoniae 
isolated from the nasopharynx in Tanzanian children with symptoms of upper 
respiratory tract infection.  
• To investigate the relation between the pneumococcal carriage rate to social factors 
and health status of the children. 
Method 
 
During October and November 2013, 188 randomly selected patients below two years of age 
seeking health care with symptoms of respiratory tract infection were included in the study. 
This study was done in parallel to another student project investigating healthy children. The 
total sample size from the two studies was 338 children.  The children attended the health 
clinics for routine care such as immunization or growth monitoring or attending out patient 
department (OPD)-clinic, care and treatment clinic (CTC) or for a few other reasons. The 
children were recruited at Bondeni and Njoro Dispensaries and Pasua Health Centre, in the 
Moshi area, which were randomly selected and approved by the Municipal Director Dr. 
Benjamin Sana (see appendix). The town of Moshi is situated in the northern zone and in the 
Kilimanjaro region of Tanzania and has a population of around 180,000 people. Translation 
and assistance at the clinics was given by experienced community health nurses from 
Kilimanjaro Christian Medical Centre (KCMC), the largest referral hospital in the northern 
zone. The questions were asked in English and then translated to Kiswahili. The inclusion 
criteria were presence of at least one of the following symptoms with or without fever: chills, 
rapid or difficult breathing, cough, running nose and sore throat. The study was based on 
voluntary consent and only 13 parents/guardians refused to participate.  
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A questionnaire was handed out to the parents/guardian to fill out (see appendix). It contained 
questions about health status, socio- economic conditions, previous illness, pregnancy 
problems, breast feeding, vaccinations, antibiotic treatment etc. The weight and height of the 
child was noted. The questionnaire was tested on two mothers of toddlers before the sample 
collection began.  
 
A nasopharyngeal sample was taken by a blue-capped E-swab (Copan diagnostics, Murrietta, 
CA) from the children, and transported cooled to the Microbiological Laboratory at KCMC in 
Moshi. The samples were cultured for the isolation of Streptococcus pneumoniae on sheep 
blood agar plates incubated over night in 34-36 °C, CO2, in closed jars supplied with CO2 
paper sachets (GasPak EZ CO2 Container System, Becton Dickinson and Company (BD), 
Sparks, MD) and CO2 indicators (BD).The remaining sample was then frozen and kept in the 
freezer (-20°C) at KCMC. Suspected pneumococci were identified by positive optochin test 
(diameter >14 mm) (Optochin 5 μg, Oxoid, Hampshire, UK).  
 
Colonies with pneumococci was suspended in 2 ml phosphate buffered saline to McFarland 
0.5. Isolates of pneumococci were then tested for antibiotic susceptibility against oxacillin 
(1μg), trimethoprim-sulphamethoxazole (1.25-23.75 μg), norfloxacin (10 μg), tetracycline (30 
μg), erythromycin (15 μg) and clindamycin (2 μg) (all from Oxoid) by disc diffusion tests on 
a Muller Hinton agar supplied with sheep blood and NAD (AppliChem, GmbH, Darmstadt, 
Germany). The agar plates were incubated over night in 34-36 °C CO2.The oxacillin-discs 
was used for screening of non- susceptibility against penicillin. Pneumococcal isolates with 
reduced sensitivity against oxacillin (diameter <20 mm) according to the disc diffusion test 
was tested by minimal inhibitory concentration, (MIC)-determination against penicillin, 
ampicillin and ceftriaxone (all 0.016-256 μg/mL, all from Biomérieux, Marcy I´Etoile 
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France). The isolates were then frozen (-20 °C) at KCMC in STGG storage medium (27), 
consisting of skim milk powder (Difco, BD Diagnostics, Sparks, MD), tryptone soya broth 
(Oxoid), glucose (Sigma Aldrich, Saint Louis, MO), glycerol and distilled water.  
 
The breakpoints used for the disc diffusion testing and the MIC-determination were from the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) published in 
January 2013 (28).  Pneumococci with a MIC of >0.06 mg/L were defined as having reduced 
susceptibility against penicillin. For further breakpoints see table 1. 
 
Table I. Antibiotic susceptibility breakpoints 
 
Antibiotic 
 
 
Sensitive 
 
Resistance 
 
Ampicillin 
 
 
MIC ≤0.5 mg/L 
 
MIC>2 mg/L 
Benzylpenicillin 
 
MIC ≤0.06 mg/L MIC>2 mg/L 
Ceftriaxone 
 
MIC ≤0.5 mg/L MIC>2 mg/L 
Clindamycin 
 
≥19 mm <19 mm 
Co-trimoxazole 
 
≥18 mm <15 mm 
Erythromycin 
 
≥22 mm <19 mm 
Norfloxacin 
 
 ≥12 mm <12 mm 
Tetracyclin 
 
≥25 mm <22 mm 
 
The field work was preceded by a course in global health at the University of Gothenburg 
during September 2013. Further education on the topic was given by Swedish SIDA in 
Härnösand during one weekend in May. Preparation for the laboratory work was done by a 
one week’s attendance at the Microbiological laboratory at University of Gothenburg.  
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Statistical methods 
 
Data analyses were done using the SPSS version 21.0. Comparisons between groups were 
performed using Fisher´s exact test. P values <0.05 were considered statistical significant. 
Ethical considerations  
 
The parent or guardian was informed that participation in the study was voluntary. They were 
informed that whether or not the patient chose to participate, the treatment at the clinic would 
not be affected. The parent or guardian willing to participate in the study then signed a 
consent form prior to the interview and sample collection. No social security number was 
noted, so the patients will not be able to be identified. The consent form will not be a part of 
further analysis. The study was carried out in accordance with existing ethical guidelines. 
Ethical clearance was obtained from College Research Ethics and Review Committee 
(CRERC) in Moshi, Tanzania (see appendix). 
Results 
 
Characteristics of study population: One child was excluded from the study due to 
being treated for a respiratory tract infection but having no current symptoms, leaving 187 
children (median age 8.5 months, range 1-24 months) for the analysis. The characteristics of 
the included children are described in Table 2. The main causes for seeking health care were 
out patient department (OPD)-clinic, growth monitoring and vaccination, only two came for 
the care and treatment clinic (CTC). 12 children came for other reasons and this mostly meant 
accompanying mother or a sibling. Regardless of which reason the children visited the health 
clinics for; they all had at least one symptom of a respiratory tract infection and were included 
in the study. The majority had running nose and cough (Table 2). 65 children had yet another 
symptom where the most common was abdominal discomfort, teeth eruption, diarrhea, 
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vomiting, skin rash, eye problem and loss of appetite. The children lived in either urban or 
semi-urban areas. The parents mainly spoke Kiswahili, but some also spoke English (data not 
shown). The majority was under one year of age (65%) and one third was under six months of 
age (33%).  
 
Table II. Study Population 
 
Recruited children 
 
n (%) 
 
 
Age (months) median, range 
 
 
8.5, 1-24 
Weight (kg), median, range 
 
8.5 , 3.4–14 
Length (cm) median, range 
 
67, 49-89 
Gender (girls: boys) 
 
94: 93 
Health clinic 
 
Pasua 
Bondeni 
Njoro 
 
 
 
121 (65) 
24 (13) 
42 (23) 
Reason for visit 
 
Vaccination 
Growth Monitoring 
OPD-clinica 
CTCb 
Other reason 
 
 
 
36 (19) 
69 (37) 
68 (36) 
2 (1.1) 
12 (6.4) 
Symptoms 
 
Fever 
Chills 
Rapid or difficult breathing 
Cough 
Running nose 
Sore throat 
Other  
 
 
48 (26) 
3 (1.6) 
14 (7.5) 
128 (68) 
159 (85) 
14 (7.5) 
65 (35) 
 
a Out patient department 
b Care and treatment clinic 
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Type of area  
 
Urban 
Semi-urban 
 
 
 
7 (3.7) 
180 (96) 
Education of mother 
 
No schooling 
Primary school 
Secondary school 
University 
 
 
 
1 (0.5) 
124 (66) 
57 (30) 
5 (2.7) 
Education of father 
 
No schooling 
Primary school 
Secondary school 
University 
 
 
 
 
1 (0.5) 
101 (54) 
72 (39) 
10 (5.3) 
 
 
Nasopharyngeal carriage: The nasopharyngeal carriage rate of pneumococci in the 
children was 39% (73/187), and most of the isolates were found in children less than one year 
of age (Table 3). The carriage rate did not differ between the three health clinics, Pasua, 
Bondeni and Njoro (36%, 46% and 43%, respectively). Almost no relation was found 
between pneumococcal carriage and social factors or health status (Table 3). 67% of the 
mothers and 55% of the fathers had primary school as the highest education and no relation 
was found between low education and pneumococcal carriage (data not shown). One father 
and one mother had never been to school. A majority slept three or less in one room and 17% 
slept more than three people in the same room, but this was not associated with carriage. 
Almost all children were breastfed (Table 3). Among the children aged 0-6 months (n=61) 9 
were exclusively breastfed, and this factor tended to be associated with more frequent carriage 
of pneumococci (p=0.070). On the other hand, predominantly breastfeeding was more 
common in children without pneumococci than in children with pneumococcal carriage (66% 
versus 30%, p=0.0093).  Half of the children (n=98), 47% of pneumococcal carriers and 56% 
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of non-carriers, had received antibiotics within the past three months (data not shown). 
Previous respiratory tract infection was slightly more common in children without 
pneumococci than colonized children, but the difference was not significant. 
 
Table III. Correlation between pneumococcal carriage and social factors and health status 
   
 Pneumococcal carriage p-value 
 yes 
(n =73), n (%) 
no 
(n=114), n (%) 
 
Age 
<1 year 
≥1 year 
 
51 (70) 
22 (30) 
 
70 (61) 
44 (39) 
 
n.s 
n.s 
Preterm birtha 6 (8.2) 13 (11) n.s 
Breastfed 68 (93) 103 (90) n.s 
Breastfed  0-6 monthsb 
Exclusively 
Predominantly 
Mixfed 
 
6 (26) 
7 (30) 
10 (43) 
 
3 (7.9) 
25 (66) 
10 (26) 
 
0.070 
0.0093 
n.s 
Family member with symptomsc 24 (33) 38 (33) n.s 
Antibiotic use 
<1 week 
≥1 -4 weeks 
>4 -12 weeks 
 
10 (14) 
17 (23) 
17 (23) 
 
28 (25) 
26 (23) 
36 (32) 
 
0.093 
n.s 
n.s 
Recent respiratory tract infectiond 21 (29) 45 (39) 0.16 
Previous episode of diarrhea 34 (47) 55 (48) n.s 
Previous episode of malaria 25 (34) 32 (28) n.s 
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Hospitalizatione 5 (6.8) 5 (4.4) n.s 
Siblings 39 (53) 66 (58) n.s 
Child<5 yearsf 16 (22) 31 (27) n.s 
 
No. of people sleeping in the same room 
1-2 
3-4 
>4 
 
10 (14) 
59 (81) 
4 (5.5) 
 
9 (7.9) 
100 (88) 
5 (4.4) 
 
n.s 
n.s 
n.s 
Smoking of parent 10 (14) 17 (15) n.s 
Indoor cooking without chimney 10 (14) 13 (11) n.s 
PCV 13 vaccination 
Partial 
Full 
 
7 (9.6) 
37 (51) 
 
13 (11) 
44 (39) 
 
n.s 
0.13 
a Birth more than two weeks before calculated date 
b If the children aged 0-6 months were breastfed, yes( n=23), no (n=38) 
c Family member sharing one or more of the symptoms  defined in the inclusion criteria 
d Defined as cough with fever, rapid or difficulty breathing or pneumonia during  the past three months 
e Admittance to hospital the past three months 
f Number of people below the age of five in the household other than the index patient 
ns= non significant 
 
Antibiotic susceptibility: A package containing laboratory materials such as antibiotic 
discs and strips was sent from the University of Gothenburg to Moshi before the study started. 
However, the package was delayed approximately three weeks during transportation. Because 
of the delay new antibiotic discs and strips were brought and tested in parallel with the old 
ones for the first ten samples of pneumococci. The result showed no significant difference 
between the new and old discs or strips and no difference at all in the classifications of strains 
into Sensitive, Intermediate and Resistant according to the EUCAST breakpoints (See 
appendix). Thus, the strips and discs that had been delayed were of good quality and were 
further used in the study. 
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All pneumococcal isolates were tested for antibiotic susceptibility with disc diffusion test and, 
when reduced sensitivity against oxacillin, with MIC-determination. The resistance rates 
against the eight different antibiotics tested for the 73 pneumococcal isolates are showed in 
Figure 1. 26% (19/73) of the isolates had reduced susceptibility against penicillin (MIC>0.06 
mg/L), however no sample was resistant (MIC>2 mg/L). One single isolate (1.4%) was 
resistant to ampicillin (MIC: 8.0 mg/L). Four isolates had reduced susceptibility against 
ceftriaxone (MIC >0.5 mg/L), two of these were resistant (MIC: 8 and 32 mg/L, respectively). 
Co-trimoxazole, erythromycin, clindamycin, norfloxacin and tetracycline were tested 
according to the disc diffusion test. All but two pneumococcal isolates (n=71, 97%) had 
reduced susceptibility against co-trimoxazole, 70 of these were resistant. Pneumococci with 
reduced susceptibility against tetracycline, erythromycin and clindamycin were 32%, 15% 
and 5.5%, respectively.  
Figure 1: Frequency of pneumococci with reduced susceptibility (I/R) against different 
antibiotics. Total specimens 73 
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No reduced susceptibility was detected against norfloxacin, which is a detector of quinolone 
resistance. 16 strains (22%) were multi- resistant, that is resistant to three or more antibiotics.  
Discussion 
 
Carriage of s. pneumoniae has been studied worldwide, but these studies are scarce in low-
income countries and are often limited to hospital-based studies. In this study, 187 children, 
below two years of age with respiratory tract symptoms attending health centres in the Moshi 
area have been sampled for assessment of nasopharyngeal pneumococcal carriage. The 
resistance pattern has been investigated and the carriage rate has been correlated to social 
factors that are known to be risk factors for pneumococcal carriage in children. The children 
were randomly selected from three different health clinics, meaning that not all children 
attending the health clinics were sampled for pneumococci, but among those that were asked, 
only 13 parents/guardians refused to participate. Most of the samples (121) were collected 
from the health centre, Pasua, compared to the two dispensaries. However, no difference in 
the carriage rate was detected between the health clinics, suggesting that the carriage rate and 
resistance pattern found in this study reflects the true carriage and resistance rate in the Moshi 
region. This is also the first study of its kind since the introduction of the pneumococcal 
conjugate vaccine, PCV13, in this region. 
 
The nasopharyngeal carriage rate among the children with symptoms of a respiratory tract 
infection found in this study was 39%. This is less than a study from 2013 conducted at 
Kilimanjaro Christian Medical Centre, KCMC, which showed a carriage rate of 56% among 
children born to HIV-positive mothers between 2005-2009 (29), it is also less than the study 
from Kenya which showed a carriage rate of 66% among healthy children (13), however, it is 
consistent with the study from Dar es Salaam, which showed a carriage rate of 35% among 
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healthy children (11).  In 2011, a longitudinal study was conducted at a sugar plantation in the 
Moshi region. Samples were taken from 80 healthy children below five years of age. The 
children were then followed over a 12 month period.  The carriage rate (from naso- or 
oropharynx) of pneumococci at the start of the study was 29% (30), which is somewhat lower 
than the carriage rate found in this study. All previous studies from the region were done 
before the introduction of the pneumococcal conjugate vaccine which could explain why the 
carriage rate found in this study is lower than in many of the other studies. It could also be 
explained by the fact that the children in this study were young (median age 8.5 months) and 
the pneumococcal carriage is known to be higher in older children (10). However, a majority 
of the pneumococcal strains isolated in this study were from children less than one year of 
age. The differences could also reflect the fact that the pneumococcal carriage rate varies 
greatly between regions and it is therefore crucial with local, continuous monitoring. 
 
Almost no relations were found between pneumococcal carriage and social factors or health 
status of the children which might be due to the small sample size. The only significant 
relation was found between the predominantly breastfed children under six months and 
pneumococcal carriage. 30% of the pneumococcal carriers had been predominantly breastfed 
compared to 66% among the non-carriers (p=0.0093). However, the groups were small, and 
the statistical comparisons were many, so it cannot be excluded that the statistical significance 
was found by chance. There was a tendency that recent respiratory tract infection was less 
common among children that carried pneumococci compared to non-carriers (29% versus 
39%, p=0.16); Perhaps the children with a recent respiratory tract infection had been treated 
with antibiotics which could lower the carriage rate of pneumococci in the nasopharynx, 
Antibiotic use within the past week also led to a tendency of lower carriage rate; 14% had 
received antibiotics within the past week in the pneumococcal group compared to 25% in the 
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non-carriers group, the same tendency was seen if antibiotic treatment had been given 
between four and 12 weeks ago (23% compared to 32%). This is consistent with other studies 
that also show lower rates of pneumococcal carriage after antibiotic use (14, 15), however, in 
this study, these relations were not significant. In the thesis by N. Oriyo, antibiotic use 
showed no effect on the pneumococcal carriage (30).  
 
A strange association (although not significant) was seen between full PCV 13 vaccination 
(meaning receiving all three doses of the vaccine) and pneumococcal carriage in this study. 
51% of the carriers had received full vaccination compared to 39% of the non-carriers. This is 
a surprising finding since pneumococcal vaccination is expected to lower the rate of 
pneumococcal carriage in the child population. Either the study is conducted too soon after 
the introduction of the vaccine, or the children carry serotypes not included in the 13-valent 
vaccine. Further analyses of the serotypes of the isolated strains will reveal the serotype 
distribution in the Moshi children and investigate the covering rate of the vaccine. 
 
The rate of pneumococci with reduced susceptibility against penicillin was high (26%) and 
high resistance to several other antibiotics was also shown. Almost all of the strains were 
resistant to co-trimoxazole. In the Dar es Salaam study from 2012; the pneumococci with 
reduced susceptibility against penicillin were 68% (MIC≥0.064 mg/L). The resistance rate in 
the Dar es Salaam study is much higher than the 26% found in this study. One could speculate 
if this difference could be due to an early effect of the PCV 13 vaccination, since the Dar es 
Salaam study was conducted before the introduction of the vaccine. Or, the difference in the 
resistance rate could be explained by the fact that Dar es Salaam is a much bigger city with a 
population of several million citizens compared to the 180,000 in Moshi and antibiotic 
resistance is known to be a bigger problem in urban settings (18).  The antibiotic use is 
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probably higher and hence resistant strains could be more widely spread in a city like Dar es 
Salaam than in a smaller town like Moshi. However, for some antibiotics the resistance rates 
were higher in Moshi compared to Dar es Salaam. The resistance rate against co-trimoxazole, 
tetracycline and erythromycin in the Dar es Salaam study was 83%, 10% and 6%, 
respectively, while the rates in this study was 97%, 32% and 15%. The multi-drug resistance 
in this study was 22% which is similar to the number found in the Dar es Salaam study (17%). 
Despite the different study populations (healthy children in the Dar es Salaam study and sick 
non-hospitalized children in this study), these rather large differences tell us how much the 
antibiotic resistance rates can vary, even within a country and local, frequent monitoring are 
needed to know which treatment is effective. 
 
It should be noted that none of the strains with reduced susceptibility against penicillin were 
resistant, all were intermediate. Pneumococci that are intermediately resistant to penicillin are 
still susceptible to penicillin administered parenterally so called benzylpenicillin or penicillin 
G. This means that patients with pneumococcal disease can still be treated with penicillin at 
hospitals where parenteral administration is possible. 
 
In the thesis by N. Oriyo, 88% of the colonized children carried a resistant strain, and 77% 
carried a multi-resistant strain. 25% of the children carried a strain resistant to penicillin and 
74% carried a strain with intermediate resistance. However, the resistance rate was highest 
against co-trimoxazole (82%) (30). These are higher figures for the pneumococci non 
susceptible to penicillin, but lower for the co-trimoxazole resistance compared with this study. 
A study from Gothenburg Sweden from 2012 shows completely different figures. The 
carriage rate among healthy toddlers was 45%, but the resistance rates were much lower than 
those found in this study (10). Pneumococcal isolates with reduced susceptibility against 
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penicillin was only 4%, although the breakpoint used for the pneumococci non-susceptible to 
penicillin was MIC≥0,125 mg/L, which is a higher limit than used in this study. The 
resistance rate against co-trimoxazole was 9,8%, but among the clinical isolates the resistance 
rates were higher (17% against co-trimoxazole and 9,3% against penicillin) (10). The study 
from Gothenburg shows the importance of not only testing clinical samples, but also testing 
children at health clinics seeking for all kinds of reasons, which might give a more accurate 
picture of prevalence of resistant strains in the community. In this study the resistance pattern 
found among the isolates is likely to reflect the prevalence of resistant S. pneumoniae in the 
Moshi region. The resistance rate is especially high against co-trimoxazole since this has been 
the cheapest antibiotics available and since it has been used as prophylaxis against 
opportunistic infections in the HIV-infected children (11, 29). The antibiotic also shares some 
components with an earlier used medicine for malaria (pyrimethamine-sulphadoxine) (30). 
These factors together explain the wide-spread resistance against this antibioticum. 
 
In the thesis by N. Oriyo many of the children were treated with antibiotics during the follow 
up time, often asymptomatically for coughs and running nose. The most common 
antibioticum prescribed was amoxicillin, followed by erythromycin (30). In this study, the 
same pattern was noticed. More than half of the children had received antibiotics within the 
past three months prior to interview and many times the antibiotics was given to treat mild 
symptoms such as running nose and cough. Surprisingly, among the children that had 
received antibiotics during the past week, 68% had got it prescribed by a doctor. The most 
prescribed antibiotics were amoxicillin and ampicillin followed by erythromycin, co-
trimoxazole/septrim and penicillin. Fortunately, the resistance rate against ampicillin was low 
(1,4%) but higher against erythromycin (15%). The high resistance rates found in this study 
can be explained by the widespread overuse of antibiotics, as compared with the Gothenburg 
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study in Sweden, where only 25% of the children had received antibiotics within the past six 
months and hence much lower resistance rates were found (10). Overuse of antibiotics in 
Moshi may danger the low resistance rates of pneumococci against amoxicillin, the 
antibioticum that is nowadays the first drug of choice against pneumonia. 
 
The HIV/AIDS epidemic has been especially prevalent in the Sub-Saharan Africa. In 
Tanzania 6% of adults between 15-49 years old are infected with the Human 
Immunodeficiency Virus, HIV (17) and almost 15,000 children die each year due to AIDS 
(25). In this study only four children had unknown HIV-status. The mother was HIV positive 
and if the virus had been transmitted to the child was currently unknown which meant that the 
four children were on treatment with ART and had prophylaxis with co-trimoxazole.  
 
A majority (91%) of the children in this study were breastfed, but only 15% of the children 
less than six months of age were exclusively breastfed; many parents had started giving water, 
soup or porridge to the children.  This is even less than the figures from Tanzania 
demographic and health survey from 2010 which states that 97% of the children in Tanzania 
are breastfed, but only half of the children are breastfed exclusively the first six months as 
recommended by the WHO. The median duration of breastfeeding is 21 months (17). The 
mothers probably breastfeed their children longer and more often exclusively in the poorer 
areas of Tanzania. The children in the Moshi area have in general good access to food and the 
need to breastfeed longer is not as big as in the more rural parts of Tanzania. 
 
Almost half (48%) of the children had at least one previous episode of diarrhea and almost a 
third (30%) had had malaria. This was not associated with pneumococcal carriage. These 
factors are not by themselves known risk factors for pneumococcal carriage, but many times 
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parents treat diarrhea and sometimes even malaria with antibiotics which can have impact on 
the pneumococcal carriage. It also shows that diarrhea and malaria are common among small 
children in the Moshi region. 
 
Strengths and weaknesses: One can discuss how representative this study population is 
for the Moshi area. The children were randomly selected, which means that not all children 
attending the three health clinics during October and November 2013 were included in the 
study. The health clinics were open Monday to Friday and most patients attended them during 
9am- 2pm. The sample collection was done during that time. A few patients might have come 
to the clinics before 9am or after 2pm and some of the parents/guardians may not have known 
about the study and left before they could be asked to participate. However, I do believe that 
during the days of sample collection, we enrolled most of the children less than two years of 
age attending the health clinic. In addition, most of the children came for vaccination or 
growth monitoring and the vaccination coverage in the Moshi region is 94%. I therefore argue 
that the results in this study are representative for the Moshi region.  
The study is based on information recalled by parent, this is of course not without problem 
and can cause recall bias, since parents tend to forget, for instance recent antibiotic use, name 
of antibiotic, recent respiratory tract infection etc.  However, the parents had some time to 
think through the questions before answering and many of the questions were asked 
repeatedly but in different ways, which could help the parents remember. The questioning of 
the parents was also done in English but translated to the parents in Kiswahili, by the 
community health nurses, which of course may lead to misinterpretations.  Despite some 
limitations at the clinical laboratory, for instance frequent power cuts and the delay of the 
laboratory package sent from University of Gothenburg, the laboratory work proceeded 
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smoothly and the material in the sent packages was double tested and found to be of good 
quality.  
The sample size in this study is 187 children. However, together with another student project, 
the sample size is 337 and further sample collection are planned to be conducted during the 
following year which will increase the study population further. This may give more accurate 
figures of the carriage and antibiotics rates, and relations to risk factors not found in this study 
may be revealed.  
All of the 187 e-swabs and the 73 pneumococcal strains found in this study are currently kept 
in a freezer at KCMC in Moshi. The samples and the e-swabs will be transported cooled to 
Gothenburg for further analysis, including real time PCR. In that way, other bacteria and 
viruses could be found and serotyping of the pneumococcus will be performed.   
Conclusion 
 
High resistance rates were discovered in this study. Penicillin and co-trimoxazole should not 
be used as empirical treatment for pneumonia, while amoxicillin and ampicillin can still be 
the first drugs of choice. Both the carriage and resistance rates will probably be influenced by 
the PCV 13 vaccination, however the effect of the vaccine is probably too early to be seen. 
The antibiotic use is excessive and further regulation on a more rational antibiotic use is 
needed in the Moshi region and may lower the resistance rates. 
Populärvetenskaplig sammanfattning 
 
Lunginflammation orsakar globalt sett mer än en miljon dödsfall hos barn under fem år varje 
år. Den viktigaste bakterien som orsakar sjukdomen är Streptococcus pneumoniae 
(pneumokocken). Bakterien finns i övergången mellan näsa och svalg (nasofarynx) hos barn 
utan att nödvändigtvis orsaka sjukdom. Det finns ett antal kända riskfaktorer för både 
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bärarskap av bakterien och för sjukdom, bl.a. låg ålder, rökning, trångboddhet, matlagning 
inomhus utan skorsten och HIV. S. pneumoniae har tidigare behandlats med penicillin, men 
en alltmer utbredd resistens mot penicillin och andra antibiotika ses över hela världen. 
Lunginflammation och antibiotikaresistens är särskilt stora problem i låg-inkomstländer. Den 
här studien syftade till att undersöka hur många barn som bär pneumokocken i nasofarynx och 
hur vanligt det är med antibiotikaresistens samt om det finns något samband mellan sociala 
faktorer och bärarskap i Moshi i Tanzania. Studien är aktuell pga. att Tanzania infört 
vaccination mot pneumokocker i januari 2013. 
 
Den här studien genomfördes på tre olika hälsocentra i Moshi-regionen i Tanzania. 187 barn 
under två år med minst ett symptom på en övre luftvägsinfektion (hosta, rinnande näsa, 
förhöjd andningsfrekvens, ansträngd andning eller halsont) och vars föräldrar gick med på att 
delta, inkluderades i studien. En pinne fördes in i näsan och ett så kallat nasofarynx-prov togs. 
Ett frågeformulär gavs till föräldrarna med frågor om hemförhållanden och barnens 
hälsotillstånd. Nasofarynx-pinnen togs med till laboratoriet på sjukhuset Kilimanjaro 
Christian Medical Centre och odlades ut enligt standard- metoder. De pneumokocker som 
hittades testades för känslighet mot flera olika antibiotika. 
 
39%  av barnen bar pneumokocken i nasofarynx. 26% av pneumokockerna hade nedsatt 
känslighet mot penicillin och nästan alla pneumokocker var resistenta mot trim-sulfa 
(septrim). Resistensen var låg mot ampicillin, ceftriaxon och clindamycin. Mot erytromycin 
och tetracyklin var den 15%, respektive 32%. Nästan inga samband hittades mellan sociala 
faktorer och bärarskap av pneumokocken.  
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Bärarskapsfrekvensen i den här studien stämmer överens med andra studier från Moshi-
regionen. Resistensen var hög mot flera olika antibiotika och den här studien bekräftar att 
trim-sulfa och penicillin inte längre ska användas som förstahandsbehandling mot 
lunginflammation, men att ampicillin (som används mycket i Moshi-regionen) fortfarande kan 
användas. Fler restriktioner av antibiotika-användningen behövs i Moshi och kan leda till 
sänkta resistensnivåer i Moshi-regionen. Effekten av den nyligen införda vaccinationen är i 
nuläget för tidig att se, men man kan förvänta sig en minskad bärarskapsfrekvens och kanske 
även en minskad antibiotikaresistens. 
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Appendices 
 
The e-test double testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
number 
Penicillin Ampicillin Ceftriaxone 
35 0,125 0,19 0,25 
35 new 0,125 0,19 0,25 
39 0,19 0,125 0,094 
39 new 0,19 0,125 0,094 
47 0,25 0,19 0,125 
47 new 0,25 0,19 0,125 
58 0,19 0,125 0,064 
58 new 0,19 0,125 0,064 
61 0,25 0,125 0,094 
61 new 0,25 0,125 0,094 
63 0,25 0,25 0,008 
63 new 0,25 0,25 0,008 
87 0,94 0,16 1,5 
87 new 0,94 0,16 1,5 
93 0,032 0,016 0,125 
93 new 0,032 0,016 0,125 
101 0,032 8 32 
101 new 0,034 8 32 
106 0,023 0,125 8 
106 new 0,023 0,125 8 
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The disc-diffusion double testing 
 
 
Sample 
Number Optochin Oxacillin 
 
SXT 
 
E 
 
DA 
 
NOR 
 
TE 
 1 25 28,9 S 23 S 28,9 S 23,9 S 20,1 S 32 S 
1 new 24,8 28,3 S 23,2 S 29 S 24,5 S 20 S 31,8 S 
2 15,3 15,4 R 8 R 12,4 R 22,8 S 19,1 S 19,1 R 
2 new 15,1 15,7 R 6 R 14,7 R 22 S 19 S 20 R 
5 22 9,2 R 12,3 R 26,2 S 22,1 S 21 S 14,2 R 
5 new 21 9,2 R 12,5 R 26,5 S 22,7 S 20,7 S 13,3 R 
7 16,6 28,4 S 21 S 27,8 S 28,7 S 17,7 S 33 S 
7 new 16,5 28,4 S 23,6 S 27,4 S 28,1 S 18 S 36,3 S 
9 14,5 25 S 8,5 R 30 S 26 S 21 S 35,5 S 
9 new 15 25 S 8 R 28,5 S 28,5 S 21,5 S 36 S 
10 20 26,9 S 6 R 34,5 S 28,6 S 25 S 38,5 S 
10 new 20 27,8 S 6 R 34 S 29,2 S 25 S 38,2 S 
14 18,1 25,7 S 18,7 S 29,1 S 25,5 S 20 S 33,8 S 
14 new 18,1 24,6 S 20,2 S 28,1 S 32,8 S 19,6 S 33,7 S 
16 24,8 12,8 R 6 R 31,2 S 29,1 S 19,2 S 32,6 S 
16 new 26,1 12,9 R 6 R 30,5 S 28,7 S 25,1 S 33,5 S 
28 18,2 23,6 S 6 R 23 S 22 S 17,3 S 38 S 
28 new 18,2 23 S 6 R 23,4 S 23 S 17,8 S 38,2 S 
30 15 21 S 6 R 30,1 S 25,1 S 18,1 S 33,2 S 
30 new 15,1 21 S 6 R 31,7 S 26,1 S 17,9 S 32,7 S 
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Municipal Council Permission 
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Ethical clearance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
Patient Questionnaire 
 
Patient Questionnaire 
 
Pneumococci in healthy children and in children with respiratory tract infections in Moshi, 
Tanzania 
 
 
ID Number of participant:………………….. 
1. Name of the facility……………………… 
2. Level  1. Health centre 2. Dispensary 
3. Main reasons for attending at health facility; tick the appropriate & multiple answers are 
possible 
      a. Vaccination of the child 
      b. Growth monitoring  
      c. OPD clinic (child is sick); symptoms………………………………………………………. 
      d. CTC clinic 
       e. Others; mention…………………………………………………………………………. 
4. Date of filling questionnaire………………………………………………………………… 
5. Name of the person filling the questionnaire………………………………………………… 
 
 
1. Date of birth of the child…………………………………… 
Age in months....................................................................................................................... 
 
2. Weight (Kgs)...................................................................................................................... 
 
3. Length (cm)........................................................................................................................ 
 
4. Gender Girl 
 Boy 
 
5. Delivery on time (meaning term or preterm baby)? 
Yes 
No, Divergence (weeks)......................................................................................... 
 Unknown 
 
6. Problems during delivery? 
No  
 Yes, Which.............................................................................................................. 
 
7. Problems during neonatal period? 
No  
 Yes, Which.............................................................................................................. 
 
8. Is the child still Breastfeeding? 
 
0. No   1.Yes 
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If YES still breastfeeding; (For children aged 0-5 months)  
  
 No  Yes 
    Have you started giving water to the child?............................................................................. 
    Have you started giving cow’s milk to the child?.................................................................... 
    Have you started giving porridge to the child?........................................................................ 
    Have you started giving juice/ soup to the child?.................................................................... 
    Have you started giving semisolids e.g. mtori?....................................................................... 
    Have you started giving solids e.g. ugali with stew?............................................................... 
 
After filling the questions above, please tick if the child is still EBF, predominantly or mixfed 
Exclusive.............................Predominantly BF............................Mix feeding…………… 
 
 
IF YES still breastfeeding; (For children aged 6 months or more) 
     Have you introduced other foods?  No  Yes 
 
IF NOT BREASTFEEDING: 
      Age of the child in months when breastfeeding was stopped……………………...... 
      The child has never been breastfed.............................................................................. 
 
 
9. Reason for clinical visit?........................................................................................................ 
 
10. Does the child have the any of the following symptoms of respiratory tract infection 
today? 
No  Yes 
Fever   ________  ________ 
Chills   ________  ________ 
Rapid or difficult breathing ________  ________ 
Cough   ________  ________ 
Running nose  ________  ________ 
Sore Throat   ________  ________ 
 Other:....................................................................................................................... 
 
11. Sudden onset of symptoms? 
 No 
 Yes 
 Unknown 
 
12. Has anyone else in your family had similar symptoms as your child in the last 14 
days? 
 No 
 Yes 
 Unknown 
 
13. Has the child used any antibiotics the week (7 days) before seeking medical care? 
No  
Yes, which.............................................................................................................. 
 
Prescribed................................................Over the counter..................................... 
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14. Has the child used cough medicine? 
 No 
 Yes, which (or contents)......................................................................................... 
 
15. Has the child used any antibiotics in the previous? 
    No Yes If yes; types 
 One month prior to interview _____ ____ __________ 
 Unknown 
  
Three months prior to interview _____ ____ __________ 
Unknown 
 
16. Has your child had any of the following respiratory tract infections (cough with 
fever, rapid breathing, difficulty in breathing, pneumonia) within the past 3 months? 
 No  
Unknown 
Yes, how many times:............................................................................................. 
 
Symptoms:.............................................................................................................. 
 
Antibiotic treatment given....................................................................................... 
  
17. Current or previous diseases  No Yes When 
 
Asthma.....................................................................................................................
Gastrointestinal infections....................................................................................... 
Measles.................................................................................................................... 
Malaria..................................................................................................................... 
HIV.......................................................................................................................... 
Lung tuberculosis.................................................................................................... 
Malformations......................................................................................................... 
Heart disease............................................................................................................ 
Other....................................................................................................................... 
 
Details (symptoms, treatment, number of times): 
 
................................................................................................................................. 
 
.................................................................................................................................  
 
18. Has the child been hospitalized within the past 3 months? 
 No  
 Yes, When............................................................................................................... 
        Why................................................................................................................. 
 
 
19. Area where you are living? 
 Type   Name of ward 
Rural area………………………………………………………………………… 
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 Semi-rural area, Size............................................................................................... 
 Semi-urban, Size..................................................................................................... 
 Urban area, Size...................................................................................................... 
 
20. Parents level of education?  
Mother    Father 
⁪ Never been to school   ⁪ Never been to school 
⁪ Primary school   ⁪ Primary school 
⁪ Secondary school   ⁪ Secondary school 
⁪ University    ⁪ University 
 
 
21. Parents current occupation?   
Mother    Father 
⁪ Employed. What....................................................... ⁪Employed. What................................ 
⁪ Self employed. What................................................ ⁪Self employed.What.......................... 
⁪ Unemployed   ⁪ Unemployed 
⁪ Student    ⁪ Student 
⁪ Other..............................................................................Other.................................................. 
 
 
22. How many siblings does this child have?.......................................................................... 
 
23. In total how many people live in your household?............................................................ 
 
Out of those how many are children under five?................................................................... 
 
24. Number of rooms in your home?......................................................................................... 
 
25. Number of people sleeping in the same room?................................................................... 
 
26. Smoking of parents or other persons in the household? 
 Yes 
 No 
 
27. How does your family cook food? 
 Electricity 
 Gas 
 Opem fire outside 
 Open fire with chimney 
 Open fire without chimney 
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27. Is your child vaccinated? Please tick vaccinations the child has received 
 
 Birth 6 weeks 10 weeks 14 weeks 9 months 18 months  
BCG        
OPV        
OPV 1        
OPV 2        
OPV 3        
Heptavalent 1 (DPT, Hep B, 
Hemophilus B) 
       
Heptavalent 2 (DPT, Hep B, 
Hemophilus B) 
       
Heptavalent 3 (DPT, Hep B, 
Hemophilus B) 
       
PCV 13 – 1        
PCV 13 – 2        
PCV 13 – 3        
Measles        
Others:        
Others:        
Others:        
 
Unknown…………………………………………………………………………………….. 
Adequately immunized for age: No  Yes 
 
 
28. If the child has siblings < 1 year, have they been vaccinated against pneumococci?  
 Yes 
 No  
 Unknown 
 
Thank you for your participation! 
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